 Home > Biochemistry News > Biotechnology News > Reduce the risk of disease progression in patients with early kidney cancer by 32%, Keytruda receives priority review qualification

Reduce the risk of disease progression in patients with early kidney cancer by 32%, Keytruda receives priority review qualification

 Last Update: 2021-08-29
 Source: Internet
 Author: User

Tags

reference materials

simple cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 10, 2021, Merck & Co.

Keytruda is a humanized monoclonal antibody that can block the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes and increasing the body's immune system's ability to detect and fight tumor cells

The results of the randomized, double-blind phase 3 trial KEYNOTE-564 showed that at a median follow-up time of 24.

In 2020, there will be more than 431,000 newly diagnosed kidney cancer cases worldwide, and more than 179,000 will die as a result

Dr.

Reference materials:

[1] FDA Grants Priority Review to Merck's Supplemental Biologics License Application for Keytruda® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery.

https:// AE-pembrolizumab-as-Adjuvant-Therapy-in-Certain-Patients-With-Renal-Cell-Carcinoma-RCC-Following-Surgery

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.